AI-generated summary
This is a study protocol describing a planned randomized pilot comparing transcutaneous 808 nm infrared photobiomodulation with intraoral 660 nm red photobiomodulation for preventing oral mucositis in head and neck cancer patients receiving radiotherapy. The authors report that no results are presented yet, and their primary hypothesis is that the transcutaneous approach is as effective as the intraoral one. The study is planned with 54 patients.
- Participants
- 54
- Who or what was studied
- Patients undergoing radiotherapy (60-70 Gy) for head and neck cancer
- Wavelengths
- 808, 660 nm
- Limits stated in the abstract
- This is a protocol with no reported results, and the abstract describes a pilot study with a small planned sample of 27 patients per group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Methods
A randomized pilot study is being conducted with 54 patients (n = 27 per group) undergoing radiotherapy (60-70 Gy) for HNC. Participants will be randomly assigned to receive either intraoral PBMT (660 nm, 100 mW, 1 J/point, fluence = 10.20 J/ cm², 10 s, 44 points) or transcutaneous PBMT (808 nm, 100 mW, 1 J/point, fluence = 34.5 J/ cm² (central) and 4.3 J/ cm² (lateral), 10 s, 32 points). Interventions occur three times weekly throughout treatment. The primary outcome is OM severity, graded by WHO scale. Secondary outcomes include OM severity (NCI-CTCAE), pain intensity (Numeric Rating Scale, NRS), ulcerated area extension, registered through digital images, treatment interruptions and unscheduled healthcare utilization. EXPECTED OUTCOMES: the primary hypothesis posits that transcutaneous infrared PBMT is as effective as intraoral red PBMT in mitigating OM severity. Additionally, the transcutaneous approach is expected to offer logistical advantages, including a reduction in application time (80 s vs. 440 s) and improved tolerability in patients with radiation-induced trismus or severe oral pain.
Conclusion
This protocol is expected to provide robust evidence to support the most feasible and effective PBMT modality for OM prevention. By optimizing treatment delivery, the study may enhance adherence, preserve nutritional status, and improve the quality of life for patients undergoing oncological therapy.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm, 660 nm
- Power
- 100 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Oral mucositis, Fluence, Laser, Primary outcome, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.